Gilead Sciences, Inc.
GILD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882095
In the last 90 days, Gilead Sciences, Inc. insiders filed 0 open-market purchases and 13 sales; 2,301 institutions reported holding it in 13F filings for Q2 2026, worth $140.5B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $210.5B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $39.5M in total
- 13
- 13F holdersQ2 2026, −6 vs. previous quarter
- 2,301
- 13F valueReported value at the end of Q2 2026
- $140.5B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $29.4B
- +2.4% year over year
- Net income, FY2025
- $8.51B
- +1,672.9% year over year
- Free cash flow, FY2025
- $9.46B
- −8.2% year over year
- Revenue, Q3 FY2026
- $8.30B
- +6.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 21.3M
- Shares sold short
- Change
- +1.00M
- +4.9% vs. previous
- Days to cover
- 3.18
- At average daily volume
Superinvestors holding GILD, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding GILD at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Gilead Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 (view filing)7:20 PM ET | Nov 6 | 3 days | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | SSale | −3.40K | $164.11 | −$557.8K | −38.8%5.36K after | 10b5-1 |
| Nov 6, 2026 (view filing)5:15 PM ET | Nov 4-5 | 2 days | O'Day Daniel PatrickChairman & CEO | SSale | −112.4K | $175.16 | −$19.7M | −16.9%551.7K after | 2 lots10b5-1 |
| Nov 2, 2026 (view filing)7:14 PM ET | Oct 30-Nov 2 | 3 days | O'Day Daniel PatrickChairman & CEO | SSale | −30.9K | $172.57 | −$5.33M | −5.3%551.7K after | 6 lots10b5-1 |
| Oct 16, 2026 (view filing)4:17 PM ET | Oct 15 | 1 day | Dickinson Andrew DChief Financial Officer | SSale | −3.00K | $156.22 | −$468.7K | −1.8%161.1K after | 10b5-1 |
| Oct 16, 2026 (view filing)4:12 PM ET | Oct 15 | 1 day | Mercier JohannaChief Comm & Corp Aff Officer | SSale | −3.00K | $156.22 | −$468.7K | −2.6%113.7K after | 10b5-1 |
| Oct 2, 2026 (view filing)4:40 PM ET | Oct 1 | 1 day | O'Day Daniel PatrickChairman & CEO | SSale | −15.0K | $147.90 | −$2.22M | −2.6%566.7K after | 2 lots10b5-1 |
| Sep 16, 2026 (view filing)4:30 PM ET | Sep 15 | 1 day | Dickinson Andrew DChief Financial Officer | SSale | −3.00K | $145.29 | −$435.9K | −1.8%164.1K after | 10b5-1 |
| Sep 16, 2026 (view filing)4:27 PM ET | Sep 15 | 1 day | Mercier JohannaChief Comm & Corp Aff Officer | SSale | −3.00K | $144.22 | −$432.6K | −2.5%116.7K after | 3 lots10b5-1 |
| Sep 2, 2026 (view filing)4:12 PM ET | Sep 1 | 1 day | O'Day Daniel PatrickChairman & CEO | SSale | −15.0K | $148.64 | −$2.23M | −2.5%577.1K after | 3 lots10b5-1 |
| Aug 27, 2026 (view filing)6:44 PM ET | Aug 26 | 1 day | Welters AnthonyDirector | SSale | −18.0K | $148.62 | −$2.68M | −58.3%12.9K after | 4 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 2,301 holdersThe largest institutional positions in Gilead Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 121,844,108 | $15.4B | 0.23% | +2,833,135+2.4% | Added |
| Vanguard Capital Management LLC | 81,091,734 | $10.2B | 0.22% | +436,958+0.5% | Added |
| FMR LLC | 66,870,816 | $8.45B | 0.37% | −5,035,474−7.0% | Reduced |
| State Street Corp | 61,216,552 | $7.73B | 0.23% | +1,357,967+2.3% | Added |
| Capital World Investors | 40,988,975 | $5.18B | 0.61% | −294,958−0.7% | Reduced |
| Invesco Ltd. | 39,819,151 | $5.03B | 0.40% | −1,761,672−4.2% | Reduced |
| Vanguard Portfolio Management LLC | 35,316,168 | $4.46B | 0.20% | +186,703+0.5% | Added |
| Geode Capital Management, LLC | 30,065,642 | $3.80B | 0.20% | +339,590+1.1% | Added |
| Price T Rowe Associates Inc | 29,996,694 | $3.79B | 0.38% | +3,748,586+14.3% | Added |
| Morgan Stanley | 24,004,354 | $3.03B | 0.16% | +705,059+3.0% | Added |
Holders of 5% or more of GILD
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Gilead Sciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.20%101.7M shares | – | Apr 24, 20251 filing | Apr 24, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 7.51%93.3M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| FMR LLC | 13G | 5.30%65.5M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |
Politician trades
All politician trades in GILD21 members of Congress reported 52 trades in Gilead Sciences, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 5, 2026 |  Tommy Tuberville Senate · AL | Sell (full) | $1K-$15K |
| Aug 5, 2026 | Tommy Tuberville Senate · AL | Buy | $1K-$15K |
| Aug 5, 2026 | Tommy Tuberville Senate · AL | Buy | $1K-$15K |
| Aug 5, 2026 | Tommy Tuberville Senate · AL | Buy | $1K-$15K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $1K-$15K |
Senate · AL · Aug 5, 2026
Sell (full)$1K-$15K
Senate · AL · Aug 5, 2026
Buy$1K-$15K
Senate · AL · Aug 5, 2026
Buy$1K-$15K
Senate · AL · Aug 5, 2026
Buy$1K-$15K
Senate · OK · Jul 21, 2026
Buy$1K-$15K